The Effect of Vitamin B12 Supplementation in Nepali Infants on Growth and Development
Phase: PHASE2
Conditions: Development, Vitamin Deficiency, Malnutrition
Sponsor: Centre For International Health

The effect of Vitamin B12 supplementation on Growth and 
Development in Nepali Infants 
 
 
 
 
 
Main protocol version 3.0 
 
April 2, 2020 
 
 
CIH: Centre for International Health, University of Bergen, Norway  
 
TU: Department of Child Health, Tribhuvan University, Nepal 
 
IHT: Department of Research, Innlandet Hospital Trust, Norway 
 
NORCE: NORCE Health, Bergen, Norway 
 
DOP: Department of Psychosocial Science, University of Bergen, Norway 
 
 
 
Principal Investigator:  
 
Tor A Strand MD/PhD (IHT/CiH) 
Professor 
Innlandet Hosptial Trust  
 
Other Investigators: 
 
Ram K Chandyo MD/PhD (TU) 
Mari Hysing PsyD/PhD (DOP) 
Ingrid Kvestad PsyD/PhD (NORCE) 
Laxman Shrestha MD (co-PI) (TU) 
Merina Shrestha MD  (TU) 
Prakash S Shrestha MD/PhD (co-PI) (TU) 
Manjeswori Ulak MD (TU/CIH) 
Suman Ranjitkar (TU) 
Shakun Sharma (TU) 
Ingvild Oma PhD (IHT) 
Catherine Schwinger PhD (CIH) 
 
 
 
 
 

Changes from version 2.1.: 
 
 
 
- 
added new objectives related to COVID-19 (symptoms, worries, and mental health , pages 5-6) 
- 
added questions on corona (COVID-19) symptoms (protocol change page 9)  
- 
added mental health questions related to corona (protocol change page 9, 10, 14, 15) 
- 
added researchers Ingvild Oma (Innlandet Hospital Trust), Shakun (Trubhuvan University), Sharma Suman 
Ranjitkar (Trubhuvan University), and Catherine Schwinger (University of Bergen) 
- 
in the plasma samples that have been collected measure nutrients and markers of inflammation in addition to the 
markers of vitamin B12 (protocol change page 8) This is justified by objective 8 (predict neurodevelopment) and 
covered by the initial consent form. 
- 
UniHealth, UniResearch changed to NORCE Health (due to change in the name of the organization, title page) 
- 
Mari Hysing changed affiliation from NORCE to DOP 
- 
We also apply to extend the project duration by 5 years (i.e. until December 31 , 2028) 
 
 

3 
 
 
 
Lay Abstract  
Rationale: Globally, vitamin B12 deficiency is one of the most common micronutrient deficiencies. The only relevant 
source of Vitamin B12 is animal-source foods. Vitamin B12 is crucial for normal cell division and is necessary for brain 
growth as well as for the maintenance of its normal function. Deficiency is also associated with impaired growth. In a 
previous study, we demonstrated that vitamin B12 administration over a period of six months enhanced growth, and 
scores on a neuro-developmental test in young Indian children. However, the overall effect was small and, for the 
developmental scores significant only in those that were malnourished at the start of the study.  
 
Our findings need to be verified in trials targeting younger, malnourished children and with longer supplementation 
time.  
 
Hypothesis: This proposed study will test three hypotheses; to measure to what extent 2 µg of vitamin B12 
administration for one year to marginally stunted children improves; 1) growth, 2) neurodevelopment, and 3) 
hemoglobin concentration. 
 
Study design: Randomized placebo-controlled trial. Half of the children will receive a paste containing vitamin B12, 
the other half the same paste but without vitamin B12.  
 
Study participants and site: 600 malnourished infants in Bhaktapur municipality in Nepal. In this population we have 
demonstrated that vitamin B12 deficiency and poor growth is common in early childhood. 
 
Intervention: Daily administration of a paste containing vitamin B12 or placebo for 12 months 
 
Data: The main outcomes of this study are scores on developmental assessments tools and growth measured every 
month for 12 months. We will also attempt to follow these children beyond the time of supplementation, i.e. beyond 
the period of this project to measure to what extent any neurodevelopmental changes persist after end of 
supplementation.  
 
Goal:  A substantial proportion of children in many low and middle-income countries suffer from poor growth, which 
is associated with poor health and poor brain development. Our goal is to identify modifiable limitations for growth 
and brain functioning in young children in poor settings. If vitamin B12 is such a limitation, increasing the intake in 
susceptible populations will be the next step. The approach will depend on the setting and what is acceptable in the 
target population. In Nepal, this can be done by promoting available inexpensive animal-source foods such as animal 
milk and eggs. In other places, routine supplementation, food fortification or even regular injections may be the most 
feasible approach. The body has the ability to store vitamin B12 for a long time, i.e. supplementation for limited time 
periods may have a long –term impact on vitamin B12 status, growth and cognitive development in many children 
worldwide. Thus, there are several non-expensive ways of improving vitamin B12 status in young children in poor 
countries if this is necessary. A recent review in the Lancet estimated that there may be more than 200 million 
children worldwide who fail to reach their developmental potential, ensuring adequate vitamin B12 status to many 
of these may help bring this too high number down. 
 

4 
 
Scientific Abstract  
 
Scientific basis: Globally, vitamin B12 deficiency is one of the most common micronutrient deficiencies. The only 
relevant source of vitamin B12 is animal-source foods. Vitamin B12 is crucial for normal cell division and 
differentiation and is necessary for the development and initial myelination of the central nervous system as well as 
for the maintenance of its normal function. Deficiency is also associated with impaired infant and child growth.  
 
In a previous clinical trial, we demonstrated that vitamin B12 administration over a period of six months enhanced 
growth and neurodevelopment in young Indian children. The overall effect on growth was significant but small. We 
saw an effect on both ponderal (weight for age z scores) and linear (height for age z scores) growth. However, the 
overall effects were driven by the effects in the subgroups of children who were wasted, underweight or stunted at 
baseline, and no effect in the children who were not malnourished at baseline. This effect modification was 
significant for all three (stunting, wasting, and underweight) baseline variables. Similarly, the effect of the 
intervention on neurodevelopmental scores was also strongest in the subgroup of children that were stunted. 
 
We have for the last 15 years undertaken studies on dietary intake and status in women and children in Bhaktapur, 
Nepal. In this site, vitamin B12 deficiency is very common. The objective of the proposed study is to measure to what 
extent administration of 2 µg of vitamin B12 to stunted children from the last half of infancy and for 12 months affect 
neurodevelopment, growth and hemoglobin concentration. 
 
Hypothesis: Daily supplementation of 2 µg of vitamin B12 in young Nepali children for 12 months improves 
neurodevelopment, growth and hemoglobin concentration. 
 
Study design: Individually randomized placebo controlled, double blind trial. Children will be identified in the 
community and children will be randomized to daily receive a paste containing vitamin B12 or a placebo paste. The 
paste will be delivered by trained field workers every day and by the caregivers on Saturdays and public holidays. 
 
Study participants and site: 600 marginally stunted children aged 6 to 11 months in Bhaktapur municipality and 
surrounding areas. 
 
Intervention: Daily administration of a paste containing vitamin B12 or placebo for 12 months. 
 
Comparator: Placebo, identical to the vitamin B12 supplements. 
 
Data: Primary outcomes: (i) neurodevelopmental scores measured by Bayley Scales of Infant and Toddler 
Development 3rd edition and the Ages and Stages Questionnaire 3rd edition after 6 and 12 months of 
supplementation (ii) growth measured by change in height for age, weight for age and weight for height z-score from 
study start to end study and growth velocity z scores during the six first and six last months of supplementation (iii) 
hemoglobin concentration after 12 months of supplementation.  Secondary: (i) cognitive development in children 
measured between 2 and 6 years after enrollment, (ii) linear and ponderal growth measured 2 to 6 years after 
enrollment, (iii) hemoglobin concentration measured 2 and 3 years after enrollment, (iv) leucocyte telomere length 
as a marker of biological age, (v) vagal tone (heart rate variability), and (vi) distractibility (eye tracking 
measurements). All secondary outcomes require additional funding.  
 
Relevance for programs and public health: Improved learning ability and growth in young malnourished children. If 
the supplementation is effective this will have consequences for dietary recommendation to malnourished children 
worldwide. In contrast to most other relevant nutritional interventions, vitamin B12 is inexpensive and our body has 
the ability to store vitamin B12, up to years. Thus, improving the status of this nutrient for a limited time period may 
have impact on learning and productivity beyond the time of administration and help to lift poor children out of the 
vicious cycle of poverty and malnutrition. 
 
 

5 
 
Hypothesis(es) and Aims   
A. Hypothesis(es) to be Tested 
 
1) Daily administration of 2 µG of vitamin B12 to 6 to 11 months old children for 12 months improves 
neurodevelopment in early childhood. 
2) Daily administration of 2 µG of vitamin B12 to 6 to 11 months old children for 12 months improves 
linear and ponderal growth. 
3) Daily administration of 2 µG of vitamin B12 to 6 to 11 months old children for 12 months improves 
hemoglobin concentration. 
 
 
 
 
 
 
 
 
 
 
 
 
B. Specific Aim(s) of the Project 
In a population of infants 6 to 11 months of age and where vitamin B12 deficiency and malnutrition is 
prevalent: 
1) measure to what extent administration of 2 µg of vitamin B12 for one year improves developmental 
scores measured by the Bayley Scales of Infant and Toddler Development 3rd edition (BSID-III) and 
the Ages and Stages Questionnaire 3rd edition (ASQ-3), 
2) measure to what extent administration of 2 µg of vitamin B12 improves length for age z-scores after 
1 year and length growth velocity Z scores  for the initial 6 and last 6 months of supplementation 
3) measure to what extent administration of 2 µg of vitamin B12 improves weight for age and weight 
for length z-scores after 1 year and growth velocity Z scores  for the initial 6 and last 6 months of 
supplementation, 
4) measure to what extent administration of 2 µg of vitamin B12 for 12 months improves hemoglobin 
concentration. 
5) identify subgroups for the above-mentioned outcomes that benefit from vitamin B12 
administration. 
6) measure to what extent vitamin B12 administration alters plasma vitamin  B12, plasma methyl 
malonic acid and plasma total homocysteine concentration. 
7) improve the competence in developmental and cognitive assessment in Nepal . 
8) in multiple regression analyses, identify predictors for early child development scores using 
variables reflecting socioeconomic status, early stimulation opportunities, morbidity, growth, and 
micronutrient status.  
9) Measure the extent to which the intervention has an impact on neurological function measured by 
heart rate variability or eye tracking 
10) Measure the extent to which the intervention or any other variables are associated with leucocyte 
telomere length.  
11) to describe the knowledge about the Covid-19 and the related preventive measures.  

6 
 
12) to describe worry about and impact on daily life of the pandemic and its relation to mental health and sleep 
among mothers and their children 
13) To examine the relation between worry and impact of the pandemic and child growth and cognition. 
14)  to assess longitudinally how former mental health is associated with mental health and worry during the 
pandemic.  
15) Measure whether mental maternal mental health is associated with neurodevelopment and growth and 
whether it modifies the effect of vitamin B12 supplementation.   
16) Measure cases of acute respiratory infections from April 2020 when the COVID-19 pandemic is expected to 
hit.  
 
 
 

7 
 
Background and Significance  
 
Vitamin B12 deficiency: Micronutrient deficiencies represent a major challenge to child health in many low and 
middle-income countries (LMIC) and may be associated with suboptimal cognitive function and poor growth (1). 
Studies in children and adults have shown that subtle vitamin B12 deficiency is common (2, 3). This is not surprising 
as the main source of vitamin B12 is animal source foods, which are expensive and for cultural and religious reasons 
often not eaten at all. Vitamin B12 is required for the folate-dependent enzyme, methionine synthase, which is 
necessary for the synthesis of methionine from homocysteine (tHcy). Methionine in its activated form, S-
adenosylmethionine, is the major methyl group donor used in human methylation reactions, including methylation of 
DNA and RNA. Impaired vitamin B12 status has consequences for DNA and protein synthesis and therefore cell 
growth and differentiation (4). Poor children who are malnourished might also have poor vitamin B12 status, which 
again may contribute to their impaired growth. Stunted growth is associated with several poor health outcomes 
including increased risk of infections and adverse brain development. 
 
Vitamin B12 and cognitive development: In observational studies, having low levels of vitamin B12 is related to 
cognitive decline and dementia in adults and elderly (5). Several studies have also shown that vitamin B12 deficiency 
is associated with cognitive deficits even at concentrations above the traditional cutoffs for deficiency (6). Although 
fewer epidemiological studies, the association between cognitive functioning and vitamin B12 status has also been 
described in children. Neonatal vitamin B12 deficiency causes failure to thrive and neurologic manifestations, which 
may become irreversible (7). A study in the Netherlands showed that infants raised on a macrobiotic diet 
(vegetarians) had delayed gross motor and speech and language development on a standardized checklist compared 
to infants on an omnivore diet (non-vegetarian) (8). In adolescence, the children raised on a microbiotic diet for the 
six first years of life had poorer performance on cognitive tests independently of current vitamin B12 status 
compared to adolescents who were raised on an omnivorous diet (9).  
 
In a cohort of young Nepalese children, intake of meat and other animal products, which are good sources of vitamin 
B12 was positively associated with cognitive performance (10). In a cohort study in North India we demonstrated that 
children with poor vitamin B12 status measured by low plasma vitamin B12, or elevated methylmalonic acid (MMA) 
or tHcy, had lower Mental development scores on the Bayley Scales of Infant and Toddler Development 2nd. edition 
(BSID-II) than those who did not have signs of vitamin B12 deficiency (11). These associations remained strong and 
significant even after adjusting for potential confounders such as socioeconomic status, maternal and paternal 
education, growth status, age, and sex and are supported by a recently completed randomized, placebo-controlled 
trial we conducted in Indian children 6 to 30 months of age (see “Supportive Preliminary Data”) (12). 
 
Brain development: The first two years of life is the most important period for brain growth and development of the 
nervous system (13).  The brain develops rapidly through neurogenesis, axonal and dendritic growth, synaptogenesis, 
myelination, and gliogenesis. These events happen at different times and build on each other (13). Small impairments 
during critical periods can have serious consequences for the brain’s structural and functional capacity with the 
possibility of persistence into adult life.  It is the functions and areas under development that are most sensitive to 
negative influences, and provide the most specific outcomes in assessments (14) (15). However, the functions under 
development at the time of negative exposure are not necessary the salient function at the time of assessment (16). 
Consequently, to fully understand findings in developmental assessments, we must consider the developmental 
timing of an exposure, in this case vitamin B12 supplementation (or lack thereof), as well as the timing of the 
assessment (14).  
 
The previously mentioned Dutch study indicated consequences of early vitamin B12 deficiency on cognitive 
performance in adolescence, independently current vitamin B12 status (17). In early childhood, children with poor 
B12 status had significant slower gross motor and speech and language development. These results indicate early 
influences to the participants developing brain, however with different developmental expressions depending on the 
timing of assessment (17). A causal relationship between vitamin B12 status and motor development was recently 
demonstrated in a randomized clinical trial: Otherwise healthy Norwegian infants who visited an outpatient clinic for 
feeding problems and who had symptoms of mild vitamin B12 deficiency (plasma tHcy > 6.5 µmol/L) were 

8 
 
randomized to receive an intramuscular injection of vitamin B12 or placebo (28). One month after the intervention, 
children who received vitamin B12 had substantially improved their motor function and experienced less 
regurgitation. The study did not, however, measure the effect of the intervention on other aspects of early child 
development.  
 
Why may vitamin B12 be important for the developing brain: Poor vitamin B12 status leads to a deﬁciency of S-
adenosylmethionine, which again causes deficient methylation reactions in the central nervous system. This can 
impair the methylation of myelin basic protein in the central as well as peripheral nervous system (6). The production 
of myelin is a key component of brain development from gestation, throughout childhood and well into middle age. 
The myelination of the brain is of importance for multiple brain systems and is highly related to neurodevelopment 
and subsequent cognitive functioning. Furthermore, vitamin B12 is important for cell division and maturation, which 
again is crucial for adequate development of the central nervous system. Vitamin B12 also contributes by serving as a 
cofactor in numerous catalytic reactions in the human body, which are required for neurotransmitter synthesis and 
functioning. Vitamin B12 deficiency may cause pernicious anemia with similar effects on cognitive development and 
functioning as anemia caused by iron deficiency (18). Vitamin B12 deficiency can also result in neuropathy through 
degeneration of nerve fibers and irreversible brain damage (19) (6) 
 
Micronutrients and cognitive development:  A recently published meta-analysis showed that supplementation with 
several micronutrients to children can improve cognitive development (20). This meta-analysis included several 
studies but only three studies in children less than 5 years of age, which is the most critical time of brain 
development. Of these three studies, only one study included vitamin B12 as part of the multi micronutrient 
formulation (21). This study showed that children, who were given fortified food that included vitamin B12, had 
significantly higher motor development scores compared to those who weren’t.  
 
Other factors that are important for cognitive development: There is sound evidence that deficient care and 
inadequate stimulation are key risk factors for adverse neurodevelopment in children. Poverty, improper care and 
malnutrition are associated and in the same pathway leading to poor development. Furthermore, the interaction 
between caregiver and child may be affected by the behavioural consequences of a child`s nutritional status and thus 
result in improper development. 
 
Negative influences during early childhood can have important consequences for brain functioning for the rest of a 
person’s life. Vitamin B12 is crucial for the developing central nervous system and even mild deficiency is associated 
with impaired neurodevelopment. Many young infants suffer from subtle vitamin B12 deficiency. Establishing a 
causal link between mild deficiency and neurodevelopment has to be done in a randomized, placebo controlled trial 
that provide adequate amounts of vitamin B12 for a sufficiently long period.  
 
If we are able to demonstrate a causal relationship between vitamin B12 and cognitive functioning in malnourished 
children in low-income countries, this may contribute to national nutrition recommendations and the recommended 
composition of complementary foods. Other trials have measured the impact of several micronutrients on growth 
and neurodevelopment in poor populations; many of these did not include vitamin B12. Most of these also failed to 
show an effect on growth or neurodevelopment. In fact, the only study on multi-micronutrient administration in 
children under the age of 5 years that had effect on neurodevelopment included vitamin B12 in their multivitamin 
formulation. Demonstrating that vitamin B12 is important for neurodevelopment and/or growth can ensure that 
vitamin B12 is included in micronutrient formulations that are recommended or available to vulnerable populations. 
This is indeed not always the case. The target population in Bhaktapur, Nepal is relatively food secure, they have 
good access to health facilities and are well off compared to other children in South Asia. Despite this, the rates of 
stunting, wasting and vitamin B12 deficiency are high. If vitamin B12 is an important growth and development –
limiting factor, supplementation of this single nutrient has the potential to improve growth and development in 
many children. In contrast to many other micronutrients, vitamin B12 can be stored in the body and the vitamin B12 
status can be improved by a bolus dose such as for vitamin A. 
 

9 
 
Telomeres and vitamins: Telomeres are the caps at the end of each strand of the DNA that protects our 
chromosomes. Telomere length is an indication of remaining cell cycles of a particular cell line in the body, and 
shorter telomeres in the individual are a sign of shortened life span. Stress may accelerate telomere shortening 
and the length of telomeres is often considered to be a biomarker of chronic stress.  
 
In a previous study in Nepal, we measured the relative telomere length in leukocytes in 66 infants using frozen 
blood. In this study, we found that, in addition to decrease by age, the telomere length was negatively associated 
with maternal vitamin B12 levels measured by plasma methylmalonic acid (MMA). Thus poor vitamin B12 
status in mothers reflected in high plasma MMA concentrations was associated with shorter telomeres in the 
offspring during infancy. In low and middle-income settings poverty is linked with a range of stressors in early 
childhood that can confound this observed and unpublished association. 
 
COVID-19 Pandemic. From March 23, Nepal has been on a lockdown because of the pandemic, as of April 1, 2020 we 
do not know how long this will last and how extensive this pandemic will be. We will not start phase three of the 
project until it is safe to make home visits and acceptable to ask the study participants to visit the study clinic. Initially 
we will keep in touch with the families by phone. During these phone contacts we will also ask questions on 
respiratory tract infection (RTI) symptoms and the study participants will be offered to speak to the study doctors if 
necessary. When the study staff ask questions on RTI symptoms, these will be recorded and hopefully contribute to 
describe the epidemic in Nepal.  
 
Markers of inflammation and other nutrients: We have measured several cytokines, CRP 
kynurenine/tryptophan ratio, alpha-1-acid glycoprotein, CRP, cytokines, neopterin in child populations in 
Bhaktapur. A striking finding is that most of these markers of inflammation are elevated even when the 
children have no signs of clinical infections. Increased incidence of infections is associated with poor 
neurodevelopmental scores. This may be due to the negative effect of Inflammation on the developing brain. 
The purpose of measuring inflammation is to estimate whether inflammation is associated with 
neurodevelopment. We can also measure possible pathways of B12 supplementation through inflammation. 
Vitamin B12 supplementation can also affect the other nutrients and all study participants are given a 
mixture with different vitamins and minerals. We will also measure these nutrients in the already collected 
plasma samples.   
 
Maternal mental health: The mental health of the parents and other family members is also critical for child 
development. After this project started in 2015, the field site has experienced a massive earthquake causing more 
than 10,000 fatalities. As of April 2020, the country is on a lockdown due to the COVID-19 Pandemic. These two large 
events come in addition to the constant struggle of the families in this community. In this regard, we it is important 
to ensure that this risk factor is captured well when identifying determinants for neurodevelopment and growth.  
 
 
Supportive Preliminary Data  
 
Vitamin B12 deficiency: We have assessed the statues and intake of several nutrients in Nepal and India for more 
than 15 years. We have found that vitamin B12 is one of the most commonly occurring deficiency and that it is linked 
with poor growth and poor cognitive development independently of other nutritional factors and other background 
variables. In the target population we have also measured nutrient deficiencies in women of reproductive age. These 
women suffer from the same nutritional deficiencies as young children, including vitamin B12 deficiency. The vitamin 
B12 results are summarized in the table below. It should be noted that the cut offs for defining vitamin B12 
deficiency in young children are not well defined. However, our findings show that the mean concentration of 
vitamin B12 is much lower, and that the mean concentrations of MMA and tHcy are higher in Nepal and India than in 
most populations in Europe and in the US. The functional markers MMA and tHcy are elevated when there is B12 
deficiency, and are very sensitive to even mild deficiency.  
 
Table. Studies on vitamin B12 status in Nepal and India 

10 
 
 
 
 
-Very low B12 < 148 pmol/L, low B12 < 222 pmol/L, high tHcy > 10 µmol/L, high MMA > 0.47 µmol/L (child), high 
MMA > 0.28 µmol/L (adult) 
-ALRI: Acute Lower Respiratory Infections 
 
Vitamin B12 and neurodevelopment. In the cohort of children in India 12 to 18 months old at enrolment, we also 
measured cognitive performance at two occasions 4 months apart (11). Both vitamin B12 and folate status were 
associated with poor developmental scores (BSID-II). From 2010 we undertook a randomized, placebo controlled trial 
funded by the Thrasher Research fund where we provided 2 µG of placebo, vitamin B12, folic acid, or both vitamins 
for six months to children aged 6-30 months at enrolment. The main objective of this trial was to measure the effect 
of vitamin B12 and/or folic acid on the incidence of infections. Neither of the nutrients led to a reduction in the 
incidence of diarrhea or respiratory tract infections. A secondary outcome of this trial was neurodevelopment 
measured by the developmental screening tool ASQ-3. We found that children who received both vitamin B12 and 
folic acid had approximately 15 points higher ASQ-3 scores than children who received placebo (P = 0.051), and these 
children had lower odds of being in the lower quartile of the ASQ-3 scores (Odds ratio 0.53, 95% CI: 0.29 - 0.99, P = 
0.048). There was no significant effect of vitamin B12 or folic acid alone. Stunted children, and children with elevated 
total homocysteine had significantly reduced odds of receiving scores in the lower quartile of the ASQ-3 scores [OR 
0.26, 95% CI 0.09-0.78, P = 0.016) and (OR 0.38, 95% CI 0.16-0.92, P = 0.032) respectively].  Children who received 
vitamin B12 and folic acid supplementation before the age of 2 years achieved 20 ASQ-3 points higher than children 
who received placebo (P=0.01). All effects were most apparent in the domains of gross motor and problem solving 
skills. 
 
Growth. In Bhaktapur Nepal, as in many other poor settings, the prevalence of childhood stunting increases by age 
after the 4th month of life. In fact, data from our ongoing MAL-ED (mal-ed.fnih.org) project demonstrates that before 
the 4th months of life less than 10% of the children are at risk for stunting (<-1 zscores length for age). When the 
cohort reached 2 years of age, approximately half of the children were stunted. These figures are supported by other 
studies in the same population during the last 15 years. Thus, the period between late infancy and their 2nd birthday 
is important for intervening against poor growth.  
 
Vitamin B12 and growth. In the completed vitamin B12 and folic acid trial in New Delhi, growth was a predefined 
secondary outcome. Compared to placebo, administration of vitamin B12 in combination with folic acid increased the 
mean weight and length by 120 g (95% CI: 3-210 g) and 0.29 cm (CI: 0- 58), respectively. When restricting the 
analyses to children that were stunted, wasted or underweight at time of randomization, the effects on all indices of 
growth (including change in Z scores height and weight for age) were stronger and statistically significant following 
vitamin B12 supplementation. We saw an effect of vitamin B12 both in children who were given folic acid as well as 
in those who were not, i.e. the effect of vitamin B12 was independent of folic acid supplementation.  Furthermore, 
the interactions between B12 administration and stunting, wasting or underweight on growth were statistically 
significant for all relevant growth outcomes (Strand, submitted).  
 
Vitamin B12 and anemia. In Nepalese and Indian children we found that approximately half of the children were 
anemic and that vitamin B12 status was associated with hemoglobin concentration (Ulak, in review 2013, Kumar, in 
press, 2013). Anemia is also linked to poor cognitive outcomes in young children in low and middle-income countries. 
Poor vitamin B12 status could explain part of this association.  
 
Own studies from Nepal
Year
1998-2000
2000-2001
2003-2007
2008-2009
Own studies fro
1998-2000
2010-2011
age
mean age
n
Location
very low B12
low B12 
high tHcy
high MMA
remarks
Ulak (submitted)
6-35 months
15.5
850
Urban
40 %
64 %
52 %
47 %
all had diarrhea
Chandyo (2003)
15-35 years
23.7
500
Urban
41 %
77 %
64 %
46 %
random sample
Unpublished 
2-35 months
13.4
499
Urban /rural
16 %
46 %
75 %
-
all had ALRI
Unpublished
2-12 months
6.8
463
Urban
17 %
46 %
62 %
57 %
random sample
om India
Taneja 2007
6-30 monhts
15.3
2200
Urban
28 %
54 %
56 %
62 %
Taneja 2013
6-30 monhts
16.1
1000
Urban
16 %
38 %
63 %
-

11 
 
Why is demonstrating a causal effect of vitamin B12 administration on neurodevelopment important. In the above 
mentioned cohort of Indian children, we demonstrated that vitamin B12 deficiency is common and associated with 
lower scores on the BSID-II mental development index (11). Vitamin B12 status was also the main predictor for 
elevated tHcy, elevated tHcy is a sign of functional vitamin B12 deficiency (22) (3). In our samples of children from 
Nepal and India, tHcy starts to rise when vitamin B12 is lower than 250 – 300 pmol/L, which is higher than the 
traditional cut-off used for defining vitamin B12 deficiency. This indicates that subtle B12 deficiency is very common. 
If there is a causal relationship between poor vitamin B12 intake and neurodevelopment, efforts should be made to 
improve vitamin B12 status in children and possibly also in pregnant women. However, before such 
recommendations are made, the above-mentioned results from observational studies and one clinical trial need to 
be verified in randomized, placebo-controlled trials designed for this purpose. Initially this should be done under 
circumstances that ensure high internal validity of the study such as in the proposed clinical trials. In this study we 
will do so by focusing on a relative narrow age range, by ensuring high compliance and by recruiting vulnerable, i.e. 
stunted, children. 
 
The clinical trial on folic acid and vitamin B12 in New Delhi was designed to measure an impact of folic acid and/or 
vitamin B12 administration on the incidence of infections. Growth and neurodevelopment were secondary 
outcomes. A study designed to measure the effect on growth and development of the central nervous system should 
provide the intervention for longer time than in a study that is designed to measure an effect on infections. 
Furthermore, the age range should be narrower and focus on children less than 2 years of age, and more 
comprehensive developmental assessment tools should be utilized in addition to or instead of ASQ-3.  
 
This proposed project is designed to measure the effect of vitamin B12 on growth, neurodevelopment and 
hemoglobin concentration. We will undertake the study within the critical window for brain development. We will 
start after other foods (in addition to breast milk) are introduced to the child and end before the child reaches 24 
months of age. This is also a population where stunting is common and, in contrast to the cohort that we have 
studied in North India, folate deficiency is virtually non-existent. The duration of vitamin B12 administration will be 
twice as long as the duration of supplementation in the study in India and the children are younger and thus with a 
greater potential for catch-up growth.  
 
Thus, we believe that the proposed study is well designed for measuring the effect of vitamin B12 on cognitive 
outcomes, growth, and on hemoglobin concentration. We will do this in a population where we have more than 15 
years of working experience 
 
 
 

12 
 
Experimental Design and Methodology  
Design: Randomized, double blind placebo controlled field trial. Enrolled children will receive placebo or vitamin B12 
daily for 12 months. 
 
The impact of supplementation with vitamin B12 will be measured using a randomized double-blind placebo-controlled 
study design. Placebo or vitamin B12 supplementation will be maintained at home for 12 months. The supplements will 
be provided by trained field workers daily and by caregivers on Saturdays and public holidays. If regurgitation/vomiting 
occur within 15 minutes of supplementation, extra dose will be given. 
 
Study site. The study site is located in Bhaktapur municipality, which is 15 km east of the capital city Kathmandu. 
Bhaktapur is an ancient city famous for its traditional temples and buildings. It is listed under UNESCO world heritage 
and one of the main tourist attractions in Nepal.  Bhaktapur is a homogenous community consisting mostly of practicing 
mixed Hindus and Buddhists. It is a peri-urban agricultural based community located 1400 m above sea level with a 
population predominated by the Newar ethnic group. The senior most member of the family is usually considered as 
the head of household. In the Bhaktapur municipality, domestic migrant workers from diverse ethnic groups work in 
several carpet factories. The local climate is humid subtropical with wet and hot season (monsoon) from May to August 
and dry and cool season from October to March. The annual average rainfall is 78.3 mm and the temperature ranges 
from -2 to 35 oC. Majority of the residents in Bhaktapur consume foods grown in the community. Rice is the staple food. 
The eating pattern varies with season, workload in the field and availability of foods. A variety of local green leafy 
vegetables are widely consumed mainly in the winter and spring season.  
 
Criteria for inclusion of children. Children will be enrolled if they fulfill the following inclusion criteria: 
*Age 6 to 11 months 
* Length for age Z scores <-1 (marginally stunted) 
* Availability of informed verbal consent 
* Plan to reside in the area for the next 12 months 
 
Overview'of'the'study'procedures
Month&of&study
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
Randomization
Intervention
n
Placebo
300
Intervention&placebo
Additional follow up
B12
300
Intervention&B12
Additional&follow&up&
Secondary&outcome
Outcome'measurements:
Weekly&visits
&
Nevrodevelopment
Breastfeeding&status
Bayley&Scales&of&Infant&Development&M&III
Morbidity&assessment
ASQM3,&ASQ:SE
Weight&M&length&at&baseline,&then&every&month&for&one&year,&and&then&1&and&2&years&after&end&supplementation
Sample&size:&300&per&group,&i.e.&600&
Assuming&a&loss&to&followMup&of&10%,&270&children&per&group&will&complete&follow&up&for&1&year.
Study'groups:
Placebo
Children&will&be&given&placebo&daily
Vitamin&B12
Children&will&be&given&2&x&RDA&daily
Nevrodevelopment
Bayley&Scales&of&Infant&Development&(BSID),&version&III
Other&appropriate&tests&
Delayed'outcomes:
Cognitive&tests&and&growth&up&to&6&years&after&end&of&follow&up

13 
 
Criteria for exclusion of children.  
- Severe systemic illness requiring hospitalization  
- Severe malnutrition, i.e. weight for height < -3 z of the WHO standard for this age group. For ethical reasons these 
children require micronutrient supplementation and adequate medical care. 
- Lack of consent 
- Taking B vitamin supplements that include vitamin B12. 
- Severe anemia (Hb < 7 g/dL). This would be a temporary exclusion and the children will be enrolled if they are 
successfully treated. 
- Ongoing acute infection with fever or infection that requires medical treatment. This would be a temporary exclusion 
and the children will be enrolled after recovery. 
 
Random allocation to intervention groups and blinding procedures. Eligible children will be allocated by block 
randomization (block sizes of 8) to one of the intervention groups outlined in the figure. supplements/placebos will be 
offered to the enrolled children according to serial numbers provided by the producer. 
 
Clinical parameters. All children will be visited weekly where we also will obtain morbidity data. At the visits, mothers 
will be asked about diarrheal illness (number and consistency of stools), symptoms of respiratory illness (cough, fast or 
difficult breathing), fever and physician visits. Weight and length/height will be measured at enrollment, every month 
and at the end of the 12 months period. Sick children that might require treatment will be referred to the study clinic 
for treatment.  
 
Laboratory parameters Blood samples will be obtained at enrollment (baseline) and at the end of the 12 months 
follow-up period for each child. Three mL of blood will be collected into vials containing EDTA as anticoagulant.  The 
plasma will be centrifuged at approx. 700 g at room temperature for 10 minutes, separated and transferred into storage 
vials, and stored at -70 degrees before analysis. 
 
The blood samples will be analyzed for 
1) Hemoglobin 
a. EDTA blood will be analyzed for hemoglobin by HemoCue B-Hemoglobin. 
b. For children where blood from the cubital vein is not obtained, capillary blood will be used for analysis 
of Hemoglobin 
2) Plasma vitamin B12, and plasma folate concentration will be estimated by microbiological assays using a 
chloramphenicol resistant strain of Lactobacillus casei and colistin sulphate resistant strain of Lactobacillus 
leichmannii, respectively (23, 24).  We will also measure plasma concentrations of total Homocysteine and 
Methyl Malonic acid which are good markers vitamin B12 status. 
3) The blood pellet will be analyzed for relative telomere length using quantitative real-time pcr. 
 
Measurements 
*Anthropometry. Weights will be measured with a portable electronic scale that measures to the nearest 0.01 kg 
(Salter). Height and length will be measured according to standard guidelines as we have done previously. Both height 
and weight will be measured in their homes every month. 
 
*Early Child development. All developmental tests will be carried out in a designated room at the field clinic (which is 
now used by the MAL-ED project for the same purpose). The main outcome of the neurodevelopment comparisons is 
the summary scores of the Bayley Scale of Infant and Toddler development 3rd. ed (Bayley-III) which is a comprehensive 
assessment tool of developmental functioning in infants and toddlers age 1-42 months. It is administered by a 
professional directly with the child. The tool provides information on functioning in different domains such as cognitive, 
communication and motor abilities. The Bayley-III represents the golden standard in assessment of this age-group and 
is widely used for research purposes. 
 
The Ages and Stages Questionnaire – 3rd ed. (ASQ-3) is an easily administered checklist of developmental status 
standardized for children 1-66 months. The screening system includes age-appropriate questionnaires for every 

14 
 
two/three-month intervals; each questionnaire contains 30 items written in a simple language. The questionnaires are 
designed to be completed by caregivers, but can also be administered by a trained examiner in a “home procedure” 
such as in this project. The ASQ-3 has five subscales: Communication, Gross motor, Fine motor, Problem solving and 
Personal social. ASQ-3 is an easily administered and robust tool, which we will use at baseline and throughout the study 
as outlined below. The ASQ-3 scores will also be compared between the study groups. 
 
The Ages and Stages Questionnaire: Social Emotional (ASQ:SE) is a screening tool on social and emotional behaviour 
in children 3-66 months (25). It consists of eight age-appropriate questionnaires, and covers domains as self-
regulation, compliance, communication, adaptive behaviours, autonomy, affect, and interactions with others. We will 
also compare the ASQ:SE scores between the study groups at end study. 
 
Alarm Distress Baby Scale (ADBB) is an instrument developed to measure social behavior and withdrawal in infants 2-
24 months old (http://www.adbb.net). The scoring is based on observation of the child, and the examination takes 
10-15 minutes. Examiners will be trained and standardized to perform the ADBB observations according to existing 
standards of the ADBB program. The ADBB observations will be performed at the study clinic during the other 
assessments. We will compare the ADBB scores between the study groups at end study. 
 
The Home Observation for the Measurement of the Environment (HOME) is a structured interview and observational 
measure of the psychosocial environment and quality of maternal responsiveness/parental practice 
(http://www.safeguardingchildren.co.uk/appendix-5.html). It has been used widely in international child 
development research and has shown to be predictive of intellectual abilities. The HOME will be performed in the 
homes of the children by trained field workers. 
 
We have previously used the ASQ-3, ASQ:SE, HOME and the Bayley-3 in our projects in Nepal and India, and all these 
tests are currently used in our studies in Nepal. The ADBB will be new for the site, but in our opinion, this examination 
will be feasible within this site due to its extensive experience with infants and young children and their families. The 
ADBB training is standardized from the developers, and therefore suitable as one of the measurements in the study. 
 
*Maternal mental health. We will assess the mental health of the mother by the following tools 4-5 years after end of 
supplementation at the same time the children will be followed up for ASQ-3 and NEPSY-II. During follow up visits, we 
will administer these questionnaires by trained research workers or psychologists.  
 
a. WHO Disability Assessment Schedule (WHODAS 2.0) 
WHODAS is s a widely used tool to measure the disability and functional impairment of individual. 
 
b. Somatic Symptom Scale (SSS-8) 
Somatic Symptom Scale is a brief self-report questionnaire used to assess somatic symptom burden of last 7 days and 
measures the perceived burden of common somatic symptoms. 
 
c. Self Reporting Questionnaire (SRQ-20) 
SRQ form will screen the mother’s psycho-somatic problems during last 30 days. 
 
d. Reducing Tension Checklist (RTC): 
Behavioral and psychosocial skills related to coping with emotional distress will be assessed with the Reducing Tension 
Checklist (RTC) that contains 10-item assessment of behavioral and psychological skills. 
Methodology 
e. Screen Time: 
This general questionnaire will capture some information about the screen time spent by mothers and their children. 
During follow up visits, we will administer these questionnaires by trained research workers or psychologists. 
 
 
 

15 
 
 
 
 
 
COVID-19: related questions: We have developed a separate structured questionnaire that includes questions on 
exposure risks, symptoms, risk of severe illness, knowledge and worries related to coronaviurus, as well as which 
preventive measure the mother is taking. During the lockdown, these questions, as well as the standard forms 
mentioned above, will be asked through telephonic interviews. During these interviews, the study staff will also give 
advice to participants who suspect that they have been infected by SARS-CoV-2. This can also ensure unnecessary 
visits to health facilities and spread of the virus. 
 
 
Heart rate variability (Vagal tone): Vagal tone assessment is a non-invasive measure of vagally mediated heart rate 
variability which provides information regarding maturation of prefrontal cortical areas of CNS. Executive functioning 
in children such as action planning, behavior and emotion control are coordinate through prefrontal areas of brain. 
Prefrontal activation has been related to an individual’s ability to coordinate action with peripheral physiological 
(e.g., cardiovascular) activation and recovery, with executive functions, emotion regulation, and mental health. 
Prefrontal activation in children and individually different developmental trajectories can predict long-term health 
outcomes and cognitive functions in later years. 
 
Methodology 
The heart rate variability measures the difference between the average height of heart rate peaks and valleys caused 
by breathing (respiratory sinus arrhythmia). For this purpose, cardiac activity is measured by means of changes in 
blood volume in arteries and capillaries detected by photoplethysmographic (PPG) sensors in three finger caps 
attached to three fingers of one hand. The hardware used are caps put on the fingertips and a recording unit “Alive - 
Clinical Version©” (Somatic Vision Inc./CA, see picture). To determine cardiac activity in sufficient length for the 
analysis of vagal tone, the “Standards of measurement, physiological interpretation, and clinical use” published by 
the “Task Force of The European Society of Cardiology and The North American Society of Pacing and 
Electrophysiology” will be followed. These standards of measurement recommend a recording length of 5 minutes in 
which the participant sits conveniently in a chair and is instructed to relax and breathe normally for this period. To 
ensure relaxation and sufficient data quality, an additional time of 3 minutes is allowed. Offline data analysis follows 
international standards and published statistical procedures, using common software solutions.  
 
Thus vagal tone assessment is correlated with the corresponding cognitive functions and low vagal tone has been 
identified as a risk factor for later psychopathology in adolescent and adulthood. The inclusion of vagal tone in the 
currently existing test protocols will add a physiological test variable complement to existing behavioral and report-
based tests and will extend our possibilities to detect influences of malnutrition in developmentally very sensitive 
domains such as executive functions and emotional regulation. Early detection of vagal tone in children suffering 
from sub-optimal nutrition or other detrimental environmental influences can enable health care professionals to 
take action before pathologies related to dysfunctional prefrontal inhibition (e.g., mood disorders) become manifest. 
Moreover, there are limited data on effect of vitamin B12 supplementation on heart rate variability. 
 
Eye tracking: The method of eye tracking involves the process of measuring points of gaze (where one is looking). For 
this purpose, a sensor bar with infrared diods will be placed below a video screen (e.g., a laptop or other monitor). 
Enrolment: 
 
 
 
 
 
 
 
Follow-up: 
6-11 mnd 
 
12-17 mnd 
 
18-23 mnd 
 
4-4.5 years 
 
7-7.5 years 
ASQ-3  
 
ASQ-3  
 
ASQ-3  
 
ASQ-3  
 
WISC-IV 
Bayley-3 
 
 
 
 
Bayley -3  
 
NEPSY-II 
ASQ:SE  
 
 
 
 
ASQ:SE  
 
ASQ:SE 
ADBB  
 
 
 
 
ADBB  
 
SRQ-20 
HOME  
 
 
 
 
Vagal tone 
 
WHODAS 2.0 
 
 
 
 
 
 
 
 
Eye tracking 
 
SSS-8 
 
 
 
 
 
 
 
 
 
 
RTC 

16 
 
On this screen, video clips can be presented showing logical tasks, how humans solve problems or interact, or other 
visual stimuli that have previously been used in studies on childhood brain development. All visual stimuli are 
harmless and without strong emotional content. The sensors measure gaze direction and fixation duration with high 
temporal resolution.  
Methodology eye tracking. 
No sensor or other device is attached to the participant/child, no movement restriction is required besides sitting on 
the parent’s lap, since head movements do not pose a problem for later analysis. Eye tracking in children and 
adolescents is safe and does not carry any health risk for the participant. It is based on infrared light emitting diodes 
that will pick up eye movements by assessing the visual reflection and change of light in the cornea. Participants sit 
usually 60 cm away from a computer screen on which they have to visually explore stimuli. The diodes are usually 
placed below the screen. Eye tracking has a long tradition and has been conducted in many clinical pediatric 
populations including studies investigating variations of normal brain development as well as neuropsychological 
assessment of developmental retardations or brain disorders. Side effects of eye-tracking are not reported as it is 
equivalent to simply watching a computer screen. A session can approximately 10 minutes. Eye-tracking sessions can 
be interrupted with numerous breaks. 
A video clip from one of the most renowned laboratories in Sweden investigating neurocognitive development with 
eye-tracking method can be found in following link 
http://www.tobiipro.com/fields-of-use/infant-child-research/developmental-psychology/ 
Hypotheses and Specific Aims 
The temporal patterns of gaze durations recorded during eye tracking test will allow conclusions on the attentional 
processing and depth of cognitive processing and conceptual understanding.  The results from eye tracking test will 
investigate variations of normal brain development as well as neuropsychological assessment of developmental 
retardations or brain disorders among Nepalese infants participating in vitamin B12 supplementation on growth and 
cognitive development. 
 
 
 
Training and quality control: 
Measuring neurodevelopment in all ages is challenging, particularly in low-income countries and in settings foreign to 
the one that the tests were developed for. We have therefore expanded the team to include two clinical 
psychologists (one Clinical neuropsychologist (Hysing) and one Clinical child and adolescent psychologist (Kvestad)) 
and one local pediatrician who specialize in child development (M Sthrestha). The salaries of Hysing and Kvestad will 
be covered by their Norwegian salaries.  
 
Before study start the team will arrange a training workshop in Nepal for the psychologists responsible for assessing 
children in the study. The psychologists will be trained and standardized in performing the ASQ-3 “home procedure” 
and the Bayley – 3. The local paediatrician, dr. Shrestha will serve as the gold standard both during training and 
throughout the study. Ten % of all sessions will be scored by two examiners to ensure appropriate inter-observer 
agreement. The standardization and quality control procedures will be similar to the procedures in the previously 
mentioned, Thrasher funded study in New Delhi, India. In this study, the field supervisors achieved and maintained a 
high inter-rater agreement. In addition, we will videotape 5% of Bayley-3 and ASQ- 3 assessments, which will be 
checked by the supervising psychologists who will give prompt feedback to the assessors.  
 
During the study period there will be regular Skype-meetings in the neurodevelopment team to discuss the progress 
in general and possible challenges faced. Hysing and Kvestad will visit the study site regularly, and additional training 
and standardizations will be organized. We will pay for their supervising visits by funds from this grant      
 
Assessment tools for the secondary outcomes 
NEPSY-II is a neuropsychological battery designed for the assessment of neurocognitive abilities in children aged 3-16 
years (26). We are currently applying this test in other studies in Bhaktapur, and are planning to use it in the follow-
up phase of the project (i.e. after end of supplementation) as a secondary outcome of the trial. To avoid a floor effect 

17 
 
(i.e. high proportion with very low scores), we will use the NEPSY-II when the children have reached 4 years of age 
together with the ASQ-3 and the ASQ:SE. 
 
WISC-IV is an extensive test of general cognitive functioning for children 6 to 17 years old. It is individually 
administered, generates an IQ score and from 2012 available in an Indian version with Indian norms. To avoid a floor 
effect, this test will be administered when children have reach 7 years of age. 
 
Intervention: 
The intervention will be provided in sachets contain 20 grams of the supplements. Each sachet will provide 1 day of 
supplements. The composition of the lipid based supplement is shown in the table below. 
CG Rieber - Compact has produced the lipid-based supplement, which is very similar to the intervention that we have 
used before. This also contain several other vitamins at approximately 1 RDA. This is to ensure that the effect of vitamin 
B12 is not limited by deficiency of other nutrients. The composition of this multi-micronutrient mixture is based on the 
UNIMAP formulation (29). 
 
Staff at CG Rieber Compact have labeled the supplements and the code that links the serial number of the packages to 
the group identity is being kept with them and with a scientist otherwise not involved in the trial. The researchers 
involved in this trial will not get this list until the analysis stage (see below). 
 
Dose of vitamin B12 
The RDA for vitamin B12 in children 1 – 3 years of age is 0.9 micrograms per day (Food and Nutrition Board, Institute 
of Medicine, National Academy of Sciences, 2002). We will give the child randomized to receive vitamin B12, 2   
micrograms B12 per day. 
 
This amount of vitamin B12 for 12 months does not constitute any health risk for the child. However, we will closely 
monitor possible adverse effects during follow-up. This will be done by observing the child for 20 minutes after the 
placebo or vitamin B12 was given. We will also ask specific questions regarding the children`s morbidity when visiting 
the homes. 
 
Co-intervention. 
All caretakers will be given dietary recommendations according to national guidelines.  
 
Children with anemia (defined according to national guidelines) will be given peroral iron.  
 
In short:  
At enrollment and end study when we will measure Hemoglobin concentration (Hb) in all children.  
Children with Hb 7 – 10 g/dL will be treated with peroral iron for 30 days and included if Hb > 10 g/dL. 
Children with Hb < 7 g/dL will not be enrolled and referred to hospital 
 
When enrolled (i.e. during the period when receiving placebo or vitamin B12): 
In children with severe palmar pallor we will measure Hb. 
Children with Hb 7 – 10  g/dL will be treated with peroral iron for 30 days (or longer if still anemic). 
Children with Hb < 7 g/dL will be referred to hospital. 
 
All children will receive 20 mg of zinc (dissolvable tablet, available locally) and oral rehydration solution if they fall ill 
with acute diarrhea. 
 
Treatment 
Children with pneumonia, dysentery or other illnesses will be treated according to the IMCI guidelines.  
 
 
 
 

18 
 
Sample size calculations 
We have powered the study to have 90% power for most relevant outcomes, which are displayed in the table below. 
The standard deviations for BSID, ASQ and Z scores are derived from previous studies in Nepal and India and 
represent “a worst case scenario” in terms of variability of the outcome measurements. The power to detect a 
difference of 4 BSID points is almost 80% even with a SD of 17. The expected SD of the BSID is normally 15. 
 
 
Power calculations –assuming a group size of 300  
 
 
 
Effect 
SD 
Power 
 
 
BSID 
4 
15 
87.3 
 
 
 
5 
15 
97.2 
 
 
 
4 
17 
78.1 
 
 
 
5 
17 
92.8 
 
 
ASQ 
15 
60 
82.8 
 
 
 
20 
60 
97.2 
 
 
Z scores 
0.2 
0.75 
87.3 
 
 
 
0.25 
0.75 
97.2 
 
 
Hemoglobin 
0.5 
1.5 
97.2 
 
 
 
0.4 
1.5 
87.3 
 
 
 
0.3 
1.5 
64.2 
 
 
BSID: Bayley Scales of Infant Development, version III 
 
ASQ: Ages and Stages Questionnaire, version III 
 
Z scores: change in Z scores from baseline to end study 
 
Hemoglobin: Hemoglobin concentration in grams per liter 
 
An effect size of 4 points corresponds to approx. .25 to .3 SD, and is a commonly used figure in such trials. We would not 
expect that a single intervention has an effect beyond this magnitude. The most important time of brain development is 
before the child reaches her 2nd birthday and small differences in brain functioning at this stage can result in larger and 
more profound differences later in life. 
 
Supervision and ensuring compliance of the daily follow-up 
Supervisors will organize the work-flow from the central office. They will also monitor the fieldworkers performance in 
the field by undertaking supervised and non-supervised visits to the field. In a random sample of the scheduled follow 
ups the supervisors will follow the field workers and observe their performance and interaction with the study 
participants. In the “unsupervised visits” they will visit the study participants after the fieldworkers have completed 
their tasks and ask questions about their performance, behavior and when possible, attempt to collect the same 
information as the field workers. We will undertake such supervised and unsupervised visits in 2% of all scheduled visits. 
 
 
Data management and analysis 
All forms will be checked manually by supervisors for completeness and consistency. The data will then be double 
entered at the field clinic into appropriate databases with computerized range and consistency checks. In this process 
there will be continuous data cleaning. Comparison of baseline features including vitamin B12 status will be made to 
confirm comparability across treatment groups. 
 
We will use the statistical software packages Stata and SAS to analyze the data.  A detailed plan for analysis of the 
main outcomes will be made before the list that links the child identity numbers to the treatment groups are 
obtained by the researchers. Data cleaning, definition of outcome variables, exclusion of cases as well as 
programming of scripts in the statistical packages will also be done before the analysis-files are merged with the 
randomization lists. The intervention groups will be coded in a way so that the researchers do not know the group 

19 
 
identities until the main analyses are finished. In these analyses there will be one variable denoting the group 
identity. The analyses will be planned and undertaken in a joint workshop attended by the involved scientists. All 
analyses will initially be done on an intent-to-treat- basis, to adjust for potential baseline differences we will use 
multiple regression models.  
 
Dissemination of the results 
The results of this trial will be published in international biomedical journal with peer review. Nepali scientists will be 
responsible for the reports describing the main outcomes of the trial. The scientific staff in Nepal is also responsible 
for rapid dissemination to local and national health authorities. This process will start as soon as possible after the 
meeting where the analysis workshop is held.  
 
Risk of the project 
A team of Nepali and Norwegian researchers that have been working together for more than 15 years will undertake 
this project. The main competence of this team is randomized controlled field trials in young South Asian children. 
Growth and cognitive development have been studied in many of our projects (see individual CVs). Our research site 
in Bhaktapur, Nepal was established in 1997 and was in 2007 selected as one of 8 international sites for the MAL-ED 
study [The Etiology, Risk Factors and Interactions of Enteric Infections and Malnutrition and the Consequences for 
Child Health and Development Project (MAL-ED) is carried out as a collaborative project supported by the Bill & 
Melinda Gates Foundation]. Two of summary scores of the MAL-ED study are growth and cognitive development. 
Thus, we have experience in using the main tools for this project. The team of supervisors, field workers and key 
scientific staff has been working together for more than a decade, which substantially reduces the risk for ”human 
friction”. 
 
We will take the following measures to ensure that our measurements are valid. 
 
1) The staff will go through extensive training before study start. Only those who reach a certain level of skills in 
measuring growth and who are interacting with the staff properly will be allowed to work as field workers. 
They will be assessed prior to study start and intra and inter observer (comparison with a gold standard) 
variability will be measured to quantify their skills. Such evaluation of the staff will also take place on regular 
intervals throughout the trial. 
2) A manual with the definitions and protocol will be kept in the field office and the field workers will at all 
times carry a short version of the manual describing their tasks. 
3) Supervised (observation of the field workers at work) and non-supervised (assessment of the quality of the 
performance of the field worker after the field worker have made a home visit) will be undertaken in 5% of 
all household visits. These quality checks will be done by the supervisors and selected randomly among the 
enrolled children. On the non-supervised visits, the supervisors will ask questions on the behavior of the field 
workers. This system ensures that misclassification of the exposure is kept to a minimum by ensuring that 
dispensing is being done.  
 
We are working closely with local and national health authorities to ensure good compliance with the community 
and the public health authorities. In the field site we have been running a clinic for 15 years. We have ensured that 
there have been at least 2 medical doctors at any time to provide free treatment and immunizations to children in 
the community. We believe that this long-standing relation ensures excellent compliance with the community and 
increases the likelihood of success of the project. 
 
Ethical considerations 
Clearance from the medical ethics committee at the Institute of Medicine and the regional ethical committee of 
Norway that is responsible for the supervising institution in Norway will be obtained before the study is initiated. All 
aspects of the study will be in agreement with the latest version of the Helsinki declaration and we will undertake 
and report the study in accordance to the guidelines of the “Consort” statement (27). The study will also be 
registered with clinicaltrials.org. 
 

20 
 
Mitigation 
During the project period, we will continue to staff a field clinic where all eligible children will be offered free 
examination and treatment for common conditions including diarrhea and ALRI. Children will be treated for common 
infections according to IMCI guidelines. 
 
Implementation strategy: 
 
Inclusion criteria 
 
- Age: 6 to 11 months 
- Either sex 
- Likely to reside in area for next 12 months 
- < -1 z scores length for age 
 
Exclusion criteria 
 
- Severe systemic illness requiring hospitalization  
- Severe malnutrition, i.e. weight for height < -3 z of the WHO standard for this age group. For ethical reasons these 
children require micronutrient supplementation and adequate medical care. 
- Lack of consent 
- Taking B vitamin supplements that include vitamin B12. 
- Severe anemia (Hb < 7 g/dL). This would be a temporary exclusion and the children will be enrolled if this is 
successfully treated. 
- Ongoing acute infection with fever or infection that requires medical treatment. This would be a temporary exclusion 
and the children will be enrolled after recovery. 
 
Figure 3: Study timeline 
 
 
 
 
Study Procedures 
 
Activity 
When 
By Whom 
Anthropometry (weight, length) 
At enrollment, every month, 12 
months post enrollment 
Field workers 
Timeline'of'study'activities'and'important'milestones
Years
1
2
3
Months
1
2
3
4
5
6
7
8
9
10 11 12
1
2
3
4
5
6
7
8
9
10 11 12
1
2
3
4
5
6
7
8
9
10 11 12
Activities
Preparing)field)site
Identification)of)households
Enrollment
Training)for)cognitive)development
Follow):)up,)cognitive)testing
Data)cleaning,)laboratory)analyses
Analysis/)writing
Milestones
Ethical)clearance,)clinical)trial)re x
Staff)trained)in)field)procedures)and)test x
1st)child)enrolled
x
field)work)finished
x
laboratory)work)commenced)(baseline)samples)
x
laboratory)work)finished)(end)study)samples)
x
1st)report)submitted
x

21 
 
Blood sample collection 
At enrollment, 12 months post 
enrollment 
Physicians, Phlebotomist 
Vitamin B12, Placebo 
supplementation 
Daily supplementation  (12 months) 
Field worker; dispensing 
Morbidity ascertainment 
Weekly throughout study period (12 
months) 
Field worker; morbidity 
ascertainment 
Referral to clinic 
Whenever predetermined criteria are 
present on a morbidity visit 
Field workers 
Referral to physician for screening for 
clinical pneumonia 
All cases having cough and high 
respiratory rates (³6 months to <12 
months RR ³45, ³12 months RR 
³35) or lower chest indrawings 
Field workers 
 
Activity 
When 
By Whom 
Diagnosis of clinical pneumonia 
Through all cases referred by Field 
worker and spontaneous visits to 
clinic 
Physician 
Diagnosis of other illnesses 
Throughout study period 
Physician 
Spontaneous visits to clinic by 
mothers 
Whenever they feel child needs to 
see a doctor 
Physician 
 
Outcome measures 
Activity 
When 
By Whom 
Anthropometric status 
Weight for age, weight for height, height 
for age at enrollment and after 12 
months of supplementation 
Field workers 
Biochemical assays  
Hemoglobin, plasma folate, B12,  tHcy 
and MMA at enrollment and after 12 
months of supplementation 
Hemoglobin will be measured on site. 
Plasma will be stored at -70 and analyzed 
in Norway (www.bevital.no) 
Neurodevelopment 
Bayley Scales of Infant and Toddler 
development 3rd. ed. at baseline and after 
12 months of supplementation 
Ages and Stages questionnaire 3rd ed. at 
baseline and after 6 and 12 months of 
supplementation 
Ages and Stages questionnaire: Socio- 
Emotional at baseline and 12 months of 
supplementation 
By trained psychologist  

22 
 
Alarm Distress Baby Scale: At baseline 
and after 12 months of supplementations 
HOME: at baseline 
 
Survey 
The study will be conducted in Bhaktapur municipality and the adjoining districts. We have been conducting clinical 
trials and observation studies in children and fertile women in this area since 1997. Currently we undertake 
observational studies that all involve cognitive testing of young children. These studies will end in 2013 and early 
2014. Prior to study start we will do a household survery and identify all households with pregnant women and infants. 
 
Screening and Consent Procedures 
Eligible and willing children will be brought to the clinic along with their caregivers. Here they will be screened by the 
physician/supervisor for eligibility criteria.  Only one child will be enrolled from each household.   
 
Prior to enrollment, informed consent will be obtained by the physician/supervisor.  An information sheet will be read 
out to the caregiver. The caregiver will sign the consent form; if the caregiver is non-literate, the consent will be 
witnessed by an impartial witness. A list of witnesses will be kept. 
 
Prior to initiating supplementation, socioeconomic details of the enrolled child will be collected, the HOME inventory 
questionnaire will be completed, weight and length will be taken, and the ADBB form filled in.  The baseline blood 
sample will be collected.  The first dose vitamin B12 or placebo will be administered to the child. The supplement will 
then be handed over to the mother. 
 
Field workers in charge of supplement administration will visit the child’s home daily on all working days and 
administer the supplement to the child.  On Saturday (which is a public holiday in Nepal), instructions will be left with 
the mother to dispense the same to the child. The supplements will be replaced by fresh jars at home by the field 
worker periodically.  
 
Morbidity visits 
A separate team of trained fieldworkers will visit the households once every week. During these visits they will ask for 
day-vice symptoms of illnesses, morbidity, visits to other treatment facilities, hospitalizations for the past 7 days.  The 
fieldworkers will also undertake a physical examination of the children that includes assessment of dehydration (if the 
child has diarrhea), respiratory rate count (if the child has symptoms of lower respiratory illness), and measure 
temperature (if caretaker reports fever). 
 
Visits of enrolled children to the study clinic 
These will occur under the following circumstances.  
- 
whenever the mother brings the child to the clinic because she feels the child needs to see a doctor. 
- 
the child is referred to the clinic by a field worker at a morbidity visit. 
- 
physician requests follow up for an illness.  Standard treatment for morbidity based on national guidelines will be 
prescribed.   
 
Verbal autopsies will be conducted by the physicians for all deaths that occur in enrolled children as early as possible 
after the child’s death. 
 
If an enrolled child is hospitalized, the field worker will record the hospitalization details. 
 
End study activities 
At end study (12 months), in all children, early child development tests by the psychologist(s), anthropometric 
measurements by field worker, and a blood sample by a physician (or laboratory technician).  
 
 
 

23 
 
Human Subjects  
 
Six hundred children will be enrolled in this study. There are no indications from the literature that the intervention is 
unsafe for the children. We will provide 2 µg of vitamin B12. This is the same dose as we provided in the previously 
mentioned study in 1,000 North Indian children. In this trial, where we monitored immediate adverse events and 
morbidity closely, vitamin B12 administration was not associated with any discomfort or harm to the children.  We 
will follow the children closely for possible side effects of the intervention in this trial also. For the first week of 
administration, field workers will wait for 30 minutes after the supplement has been given to observe any potential 
side effects. 
 
The lipid-based vehicle that we will deliver the vitamin and co-interventions in has also been used in several 
populations with no associated health risk. The vehicle contains, however, traces of peanuts and may pose some 
hazard to children who are allergic to peanuts. We will therefore ask the caregivers if the children have had an 
allergic reaction to peanuts and exclude these children from the study. It should be noted that in the study in North 
Indian children there were no reports of peanut allergy and no child had an allergic reaction because of the 
supplements that we gave.  
 
All children that are enrolled in this study will be offered free treatment in the field clinic and the field staff will follow 
them closely. Thus, participation in this trial will benefit the children.  
 
The research will follow International, Nepali and Norwegian ethical guidelines and the study will not be started 
before we have approval from the relevant ethical review boards in these countries. The trial will also be registered 
in clinicaltrials.gov. 
 
Participation will also be voluntary and if the caregivers chose to withdraw their child, they are free to do so at any 
time without loosing their benefits that we have offered them (except he close follow up) 
 
We will follow international standards of keeping the computerized data. Only the involved researchers will have 
access to the data and the personal information that includes names, addresses or GPS coordinates will not be kept 
with the files used for statistical analyses. These lists will be stored electronically on devices not connected to the 
internet. 
 
 
 
 
 
 
 
 
Literature References  
 
1. 
Black MM. Micronutrient deficiencies and cognitive functioning. J Nutr 2003;133(11 Suppl 2):3927S-31S. 
2. 
Allen LH. Folate and vitamin B12 status in the Americas. Nutrition reviews 2004;62(6 Pt 2):S29-33; discussion S4. 
3. 
Taneja S, Bhandari N, Strand TA, et al. Cobalamin and folate status in infants and young children in a low-to-middle 
income community in India. Am J Clin Nutr 2007;86(5):1302-9. doi: 86/5/1302 [pii]. 
4. 
Shane B, Stokstad EL. Vitamin B12-folate interrelationships. Annual review of nutrition 1985;5:115-41. 
5. 
Selhub J, Morris MS, Jacques PF, Rosenberg IH. Folate-vitamin B-12 interaction in relation to cognitive impairment, 
anemia, and biochemical indicators of vitamin B-12 deficiency. Am J Clin Nutr 2009;89(2):702S-6S. doi: 
ajcn.2008.26947C [pii]10.3945/ajcn.2008.26947C. 
6. 
Smith AD, Refsum H. Vitamin B-12 and cognition in the elderly. Am J Clin Nutr 2009;89(2):707S-11S. doi: 
10.3945/ajcn.2008.26947D. 
7. 
Bjorke Monsen AL, Ueland PM. Homocysteine and methylmalonic acid in diagnosis and risk assessment from infancy to 
adolescence. Am J Clin Nutr 2003;78(1):7-21. 

24 
 
8. 
Schneede J, Dagnelie PC, van Staveren WA, Vollset SE, Refsum H, Ueland PM. Methylmalonic acid and homocysteine 
in plasma as indicators of functional cobalamin deficiency in infants on macrobiotic diets. Pediatr Res 1994;36(2):194-
201. 
9. 
Louwman MW, van Dusseldorp M, van de Vijver FJ, et al. Signs of impaired cognitive function in adolescents with 
marginal cobalamin status. Am J Clin Nutr 2000;72(3):762-9. 
10. 
Siegel EH, Stoltzfus RJ, Kariger PK, et al. Growth indices, anemia, and diet independently predict motor milestone 
acquisition of infants in south central Nepal. J Nutr 2005;135(12):2840-4. doi: 135/12/2840 [pii]. 
11. 
Strand TA, Taneja S, Ueland PM, et al. Cobalamin and folate status predicts mental development scores in North Indian 
children 12–18 mo of age. 2013. doi: 10.3945/ajcn.111.032268. 
12. 
Kvestad I, Taneja S, Kumar T, Mohan M, Bhandari N, Strand TA. Administration of Vitamin B12 and Folic acid 
improves developmental scores in young North Indian children. Manuscript 2013. 
13. 
Thompson RA, Nelson CA. Developmental science and the media. Early brain development. The American psychologist 
2001;56(1):5-15. 
14. 
Walder D. J., Sherman J. C., Pulsifer M. B. Neurodevelopmental Assessment. . Evidence-Based Practice in Infant and 
Early Childhood Psychology 2009:167-205. 
15. 
Anderson V, Spencer-Smith M, Leventer R, al e. Childhood brain insult: can age at insult help us predict outcome? Brain 
2009;132:45-56. 
16. 
Cusick SE, Georgieff MK. Nutrient supplementation and neurodevelopment: timing is the key. Arch Pediatr Adolesc Med 
2012;166(5):481-2. doi: 10.1001/archpediatrics.2012.199. 
17. 
Dagnelie PC, van Staveren WA. Macrobiotic nutrition and child health: results of a population-based, mixed-longitudinal 
cohort study in The Netherlands. Am J Clin Nutr 1994;59(5 Suppl):1187S-96S. 
18. 
Dror DK, Allen LH. Effect of vitamin B12 deficiency on neurodevelopment in infants: current knowledge and possible 
mechanisms. Nutrition reviews 2008;66(5):250-5. doi: 10.1111/j.1753-4887.2008.00031.x. 
19. 
Calvaresi E, Bryan J. B vitamins, cognition, and aging: a review. The journals of gerontology Series B, Psychological 
sciences and social sciences 2001;56(6):P327-39. 
20. 
Eilander A, Gera T, Sachdev HS, et al. Multiple micronutrient supplementation for improving cognitive performance in 
children: systematic review of randomized controlled trials. Am J Clin Nutr 2010;91(1):115-30. doi: 
10.3945/ajcn.2009.28376. 
21. 
Faber M, Kvalsvig JD, Lombard CJ, Benade AJ. Effect of a fortified maize-meal porridge on anemia, micronutrient 
status, and motor development of infants. Am J Clin Nutr 2005;82(5):1032-9. 
22. 
Bjørke Monsen AL, Ueland PM. Homocysteine and methylmalonic acid in diagnosis and risk assessment from infancy to 
adolescence. Am J Clin Nutr 2003;78(1):7-21. 
23. 
O'Broin S, Kelleher B. Microbiological assay on microtitre plates of folate in serum and red cells. J Clin Pathol 
1992;45(4):344-7. 
24. 
Kelleher BP, Walshe KG, Scott JM, O'Broin SD. Microbiological assay for vitamin B12 with use of a colistin-sulfate-
resistant organism. Clin Chem 1987;33(1):52-4. 
25. 
Squire M, Bricker D, Twombly E. Ages and stages questionnaires: Social-emotional. Baltimore: Brookes publishing, 
2002. 
26. 
Brooks BL, Sherman EM, Strauss E. Test Review: NEPSY-II: A DevelopmentalNeuropsychological Assessment, Second 
Edition. Clinical Neuropsychology 2010;16:80-1001. 
27. 
Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of 
reports of parallel-group randomised trials. Lancet 2001;357(9263):1191-4. 
28 
Torsvik, I., Ueland, P. M., Markestad, T., & Bjorke Monsen, A.-L. (2013). Cobalamin supplementation improves motor 
development and regurgitations in infants: results from a randomized intervention study. American Journal of Clinical 
Nutrition. doi:10.3945/ajcn.113.061549 
29 
Christian, P. (2010). Micronutrients, birth weight, and survival. Annual Review of Nutrition, 30, 83–104. 
doi:10.1146/annurev.nutr.012809.104813 
 
 
 

25 
 
Collaborative Arrangements 
The group of researchers behind this project is from the Centre for International Health and Faculty of 
Psychology at the University of Bergen, and from the Institute of Medicine at Tribhuvan University. We 
have established a project management team (PMT), which we have divided into three domains. A scientist 
from the “neurodevelopmental assessment” domain will be the first author on the report (publication) on 
neurodevelopment (primary objective 1) and scientist from the “Field implementation” domain will be the 
first author on the reports on the effect of vitamin B12 supplementation on growth and hemoglobin 
concentration. As in our previous projects, we will attempt to secure funding for junior, key Nepali 
scientists so they can pursue master or PhD degrees at the University of Bergen using data collected in this 
project.  
 
 
Project management team (PMT): 
Current members:  
Coordinators: IoM: Prakash S Shrestha (MD - pediatrics), UoB: Tor A Strand (MD/PhD - Nutrition) 
Field implementation: Ram K Chandyo (MD/PhD pediatrics), Manjeswhori Ulak (MD pediatrics) 
Cognitive assessment: IoM: Merina Shrestha (MD Pediatrics), UoB: Ingrid Kvestad (Phd - Clinical child and 
adolescent psychologist), Mari Hysing (Phd – Clinical Neuropsychologist). 
 
The project management team will be expanded to include scientists with laboratory experience. 
 
The principal investigator will visit the field site 3-4 times every year during the data collection period. Most 
of the travels for this purpose will be covered from other sources. In addition, we will have regular Skype 
meetings. Initially these will be quite frequent, i.e. every week, after the study has started we will schedule 
monthly meetings. The calls will include at least one member from of each of the domains of the PMT. 
 
The questionnaires, computer entry system, and standard operating procedures will be developed jointly 
by the PMT. 
 
The members of the neurodevelopmental assessment team are currently working together on other 
studies on the assessment of neurodevelopment and cognition in early childhood.